Company intelligence / Profile preview

ELPIS SYSTEMS

Lexington, Massachusetts, United Stateselpissystem.com ↗

Ownership: Private
Employees: ~11
Development stage: Other

Overview

Elpis’s lead bispecific armored CAR-T programs have demonstrated potent tumor regression, long persistence, robust immune modulation at lower doses in preclinical models. The company has presented new data showing their multi-mechanism armor can overcome tumor microenvironment resistance by fusing engineered IL‑2 with anti-PD-L1 antibodies. Early results suggest potential for improved safety and durable responses in solid tumors.

Therapeutic areas: Oncology
Modalities: Bispecific monoclonal antibodyCAR-T cell therapyImmuno-modulatorProtein Therapeutics
Industry: Biotech

Beyond the preview

Go deeper on ELPIS SYSTEMS.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ELPIS SYSTEMS.

Explore the full profile